Cullen Frost Bankers Inc. Has $7.16 Million Position in Kenvue Inc. (NYSE:KVUE)

Cullen Frost Bankers Inc. boosted its position in Kenvue Inc. (NYSE:KVUE) by 6.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 335,273 shares of the company’s stock after buying an additional 21,057 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Kenvue were worth $7,158,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of KVUE. Grove Bank & Trust lifted its stake in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue during the 4th quarter valued at $29,000. SRS Capital Advisors Inc. increased its holdings in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC lifted its stake in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after buying an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in shares of Kenvue during the 3rd quarter worth about $35,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of research reports. Citigroup decreased their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Canaccord Genuity Group raised their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Barclays decreased their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $23.75.

Kenvue Trading Up 0.6 %

KVUE opened at $23.18 on Friday. The company’s 50 day moving average is $21.60 and its 200-day moving average is $22.31. The company has a market cap of $44.29 billion, a P/E ratio of 43.73, a PEG ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.54%. Kenvue’s dividend payout ratio is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.